XML 10 R4.htm IDEA: XBRL DOCUMENT v3.24.3
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Total revenue $ 864.4 $ 742.8 $ 2,386.8 $ 2,110.0
Total cost of revenue 445.6 360.0 1,230.6 1,027.0
Gross profit 418.8 382.8 1,156.2 1,083.0
Operating expenses:        
Selling, general and administrative 229.9 177.6 646.5 518.2
Research and development 98.1 71.3 272.1 211.3
Other charges, net 22.7 9.4 56.6 20.1
Total operating expenses 350.7 258.3 975.2 749.6
Operating income 68.1 124.5 181.0 333.4
Interest and other income (expense), net (12.8) (5.3) (30.2) (30.1)
Income before income taxes, equity in income (losses) of unconsolidated investees, net of tax, and noncontrolling interests in consolidated subsidiaries 55.3 119.2 150.8 303.3
Income tax provision 14.8 30.8 50.7 80.6
Equity in income (losses) of unconsolidated investees, net of tax (0.2) 0.3 (0.2) 1.2
Net income 40.3 88.7 99.9 223.9
Net income (loss) attributable to noncontrolling interests in consolidated subsidiaries (0.6) 0.6 0.5 2.2
Net income attributable to Bruker Corporation $ 40.9 $ 88.1 $ 99.4 $ 221.7
Net income per common share attributable to Bruker Corporation shareholders:        
Basic $ 0.27 $ 0.6 $ 0.67 $ 1.51
Diluted $ 0.27 $ 0.6 $ 0.67 $ 1.5
Weighted average common shares outstanding:        
Basic 151.5 146.6 148.1 146.7
Diluted 152 147.3 148.7 147.5
Product        
Total revenue $ 709.3 $ 615.1 $ 1,950.6 $ 1,741.8
Total cost of revenue 349.3 293.0 967.0 823.0
Other        
Total revenue 155.1 127.7 436.2 368.2
Total cost of revenue $ 96.3 $ 67.0 $ 263.6 $ 204.0